[
    {
        "molecule_name": "38R",
        "protein_target_name": "α7-5HT3 Q79G",
        "binding_metric": "EC50",
        "value": "1.6",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    },
    {
        "molecule_name": "132S",
        "protein_target_name": "α7-5HT3 W77F",
        "binding_metric": "EC50_MP",
        "value": "4.3 ± 0.5",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    },
    {
        "molecule_name": "88S",
        "protein_target_name": "mutant receptor",
        "binding_metric": "EC50_Mp",
        "value": "0.1 ± 0.1",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    },
    {
        "molecule_name": "89S",
        "protein_target_name": "mutant receptor",
        "binding_metric": "EC50_Mp",
        "value": "0.4 ± 0.1",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    },
    {
        "molecule_name": "38R",
        "protein_target_name": "α7-5HT3 Q79G Q139M",
        "binding_metric": "EC50_Mp",
        "value": "0.23 ± 0.07",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    },
    {
        "molecule_name": "22S",
        "protein_target_name": "α7-5HT3 Q79G Q139M",
        "binding_metric": "EC50_Mp",
        "value": "0.06 ± 0.04",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    },
    {
        "molecule_name": "22S",
        "protein_target_name": "α7-5HT3 Q79G Q139G",
        "binding_metric": "EC50i_ss",
        "value": "2.7 ± 1.0",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    },
    {
        "molecule_name": "22S",
        "protein_target_name": "α7-5HT3 Q79G Q139G",
        "binding_metric": "EC50i_peak",
        "value": "11.6 ± 3.6",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    },
    {
        "molecule_name": "ACh",
        "protein_target_name": "α7-5HT3 Q79G Q139G",
        "binding_metric": "EC50i_peak",
        "value": "296 ± 64",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    },
    {
        "molecule_name": "ACh",
        "protein_target_name": "α7-5HT3 Q79G",
        "binding_metric": "EC50_Ipeak",
        "value": "38 ± 2",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    },
    {
        "molecule_name": "ACh",
        "protein_target_name": "α7-5HT3 Q79G L141S",
        "binding_metric": "EC50i_peak",
        "value": "356 ± 16",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences with specific molecule names, bioactivity metrics, numeric values, and units:\n\n1. One exception was the interaction of 38R with α7-5HT3 Q79G (EC50 = 1.6 μM, no activity against α7-5HT3 wt).\n2. EC50s for activating these mutant chimeric receptors for these three compounds were in the range of 0.8-3 μM.\n3. Compound 132S (EC50<sub>MP</sub> = 4.3 ± 0.5 μM), a fluorinated analog of 28S, selectively activated α7-5HT3 W77F over receptors with the Q79G and L141F mutations.\n4. The dimethoxy derivatives, 88S and 89S, exhibited 5-10 fold improvement in efficacy against this mutant receptor (EC50<sub>M</sub>p, 88S: 0.1 ± 0.1 μM; 89S: 0.4 ± 0.1 μM) while exhibiting no activity against the α7-5HT3 wt receptor.\n5. 19S OMe H H H 1.4 ± 0.2\n6. 85S OEt H H H 1.4 ± 0,2\n7. 86S OMe H Me H 1.4 ± 0.3\n8. 87S OMe OMe H H 7.8 ± 2.1\n9. 88S Ofv e H OMe H 0 .12 ± 0. 01\n10. 89S Ofv Ie H H OMe 0 .40 ± 0. 01\n11. 90S OMe H Cl H 1.3 ± 0.3\n12. 118S OMe H H Cf 2,6 ± 0.3\n13. 109S 4-TH P H H H >1OO\n14. 125S OCF3 H H H >100\n15. α7-5HT3 Q79G Q139M showed, relative to α7-5HT3 Q79G, 8- and 20-fold improvement in efficacy over with 38R (EC50<sub>M</sub>p = 0.23 ± 0.07 μM) and 22S (EC50<sub>M</sub>p = 0.06 ± 0.04 μM), respectively.\n16. W77F 5HT3 28S 3.0(0.1} \n17. Q79G 5HT3 8.2(2} \n18. 22S 0.8(0.2) \n19. 38R 1.5(0.2) \n20. 165S 1.9(0.4) \n21. α7-5HT3 Q79G Q139G retained responsiveness to 22S (EC50i<sub>ss</sub> = 2.7 ± 1.0 μM, EC50i<sub>pea</sub>k = 11.6 ± 3.6 μM), while for ACh (EC50i<sub>pea</sub>k = 296 ± 64 μM) the additional Q139G mutation resulted in a nearly 8- fold shift in efficacy from α7-5HT3 Q79G (ACh: EC50<sub>Ipea</sub>k = 38 ± 2 μM).\n22. α7-5HT3 Q79G L141S there was only slight shift in the efficacy for 9S, but ACh responsiveness (EC50i<sub>peak</sub> = 356 ± 16 μM) shifted nearly 10-fold with addition of the L141S mutation. \n23. L141F 5HT3 198 1.4(0.2) \n24. 888 0.1(0.1) \n25. 898 0.4(0.1) 0.7(0.2) 3.2(0.5)\n26. 212 0.75 \n27. 241 0.1 \n28. L141F GIvR nd 190(120) \n29. 89S 1 8(04) \n30. 118S 3.0(0.8) 32(0.4)\n31. 119S nd 25(0.4} 38( 9)\n32. L141F Y115F GIyR nd 490(230) 590(200)\n33. 89S nd 5.2(1.9} 69(1.9)\n34. Q79G GIyR 22S nd 4.8(1.2) 75(2.4)\n35. L141F GA3AC 89S 4.9(3.2) 88(1.4)"
    }
]